The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ( ...

New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...

The author writes "In the realm of insurance coverage litigation, whether two or more claims filed in different time periods ...

King as its new Chief Commercial Officer. King brings over 25 years of experience in biotechnology, notably leading the commercial launch of Soliris® for generalized Myasthenia Gravis (gMG) at Alexion ...

King brings over 25 years of experience in biotechnology, notably leading the commercial launch of Soliris® for generalized Myasthenia Gravis (gMG) at Alexion Pharmaceuticals (NASDAQ:ALXN).

UK health watchdog NICE has given its blessing to NHS funding for Alexion's Soliris, a treatment for an ultra-rare genetic disorder, which is said to be the most expensive drug in the world.

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number of FDA-approved biosimilars to 63. Forty-one of those biosimilars have ...

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical firm. The Seoul Central District Court ruled ...